Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Azilsartan Medoxomil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 known ✓ | P30556 | 2/20 | 0.49 |
| ▸ | AGTR2 | P50052 | 3/20 | 1.00 |
| ▸ | PPARG | P37231 | 3/20 | 0.49 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.49 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.45 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azilsartan Medoxomil SCHEMBL29861385 | 1.00 | AGTR2 (1.00) | AGTR2PPARGABCB11CYP3A4AGTR1 | |
| Azilsartan Medoxomil SCHEMBL967309 | 0.99 | AGTR2 (0.99) | AGTR2PPARGABCB11CYP3A4AGTR1 | |
| Azilsartan Medoxomil SCHEMBL967313 | 0.99 | AGTR2 (0.99) | AGTR2PPARGABCB11CYP3A4AGTR1 | |
| Azilsartan Medoxomil SCHEMBL968583 | 0.99 | AGTR2 (0.99) | AGTR2PPARGABCB11CYP3A4AGTR1 | |
| Azilsartan Medoxomil SCHEMBL30770646 | 0.99 | AGTR2 (0.99) | AGTR2PPARGABCB11CYP3A4AGTR1 | |
| Azilsartan Medoxomil SCHEMBL965769 | 0.99 | AGTR2 (0.99) | AGTR2PPARGABCB11CYP3A4AGTR1 | |
| Azilsartan Medoxomil SCHEMBL965772 | 0.99 | AGTR2 (0.99) | AGTR2PPARGABCB11CYP3A4AGTR1 | |
| SCHEMBL18405788 | 0.95 | AGTR2 (0.91) | AGTR2PPARGABCB11CYP3A4AGTR1 | |
| SCHEMBL683700 | 0.94 | AGTR2 (0.90) | AGTR2PPARGABCB11CYP3A4AGTR1 | |
| SCHEMBL15456840 | 0.93 | AGTR2 (0.87) | AGTR2PPARGABCB11CYP3A4AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 568 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117126150-B | Preparation method of azilsartan medoxomil potassium salt impurity a | 仁合益康集团有限公司 | 2026-05-15 | — | — | CN | claimed |
| EP-4710928-A2 | METHODS OF TREATING IGA NEPHROPATHY WITH ATRASENTAN | Chinook Therapeutics, Inc. (US) | 2026-03-18 | — | — | EP | claimed |
| EP-4684832-A2 | POTASSIUM-BINDING AGENTS FOR TREATING HYPERTENSION AND HYPERKALEMIA | Vifor (International) Ltd. (CH) | 2026-01-28 | — | — | EP | claimed |
| EP-2916851-B1 | POTASSIUM-BINDING AGENTS FOR TREATING HYPERTENSION AND HYPERKALEMIA | VIFOR INT LTD (CH) | 2025-12-17 | — | — | EP | claimed |
| EP-4076652-B1 | A PHARMACEUTICALLY ACCEPTABLE SALT OF ATRASENTAN FOR USE IN A METHOD OF TREATING IGA NEPHROPATHY | CHINOOK THERAPEUTICS INC (US) | 2025-12-03 | — | — | EP | claimed |
| US-20250352511-A1 | METHODS OF TREATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS WITH ATRASENTAN | CHINOOK THERAPEUTICS INC (US) | 2025-11-20 | — | — | US | claimed |
| WO-2025122021-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF), THROUGH TARGETING OF S100A9 AND CORRESPONDING DIMER PARTNER AND RECEPTORS | I3S - INSTITUTO DE INVESTIGAÇÃO E INOVAÇÃO EM SAÚDE, ASSOCIAÇÃO (PT) | 2025-06-12 | — | — | WO | claimed |
| WO-2025122600-A1 | COMPOSITIONS AND METHODS FOR TREATING ABERRANT NITROSYLATION | CASE WESTERN RESERVE UNIVERSITY (US) | 2025-06-12 | — | — | WO | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| WO-2025093735-A2 | AGENTS FOR USE IN THE TREATMENT OF TAUOPATHIES | DRUG TARGET IP B.V. (NL) | 2025-05-08 | — | — | WO | claimed |
| US-20100204252-A1 | METHODS OF TREATING HYPERTENSION WITH AT LEAST ONE ANGIOTENSIN II RECEPTOR BLOCKER AND CHLORTHALIDONE | TAKEDA PHARMACEUTICALS NORTH AMERICA, INC. (US) | 2010-08-12 | — | — | US | claimed |
| WO-2010075347-A2 | METHODS OF TREATING HYPERTENSION WITH AT LEAST ONE ANGIOTENSIN II RECEPTOR BLOCKER AND CHLORTHALIDONE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-07-01 | — | — | WO | claimed |
| US-20090308780-A1 | Medicinal package | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-12-17 | — | — | US | claimed |
| US-20090270464-A1 | Benzimidazole derivative and use as a II receptor antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-10-29 | — | — | US | claimed |
| EP-1857457-B1 | Benzimidazole derivative and its use as AII receptor antagonist | TAKEDA PHARMACEUTICAL (JP) | 2009-08-19 | — | — | EP | claimed |
| US-7572920-B2 | Benzimidazole derivative and use as a II receptor antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-08-11 | — | — | US | claimed |
| EP-1718641-B1 | BENZIMIDAZOLE DERIVATIVE AND ITS USE AS A II RECEPTOR ANTAGONIST | TAKEDA PHARMACEUTICAL (JP) | 2007-08-15 | — | — | EP | claimed |
| US-7157584-B2 | Benzimidazole derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-02 | — | — | US | claimed |
| US-20060281795-A1 | Benzinidazole Derivative and Use As AII Receptor Antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-12-14 | — | — | US | claimed |
| US-20050187269-A1 | Benzimidazole derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2005-08-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204252-A1 | METHODS OF TREATING HYPERTENSION WITH AT LEAST ONE ANGIOTENSIN II RECEPTOR BLOCKER AND CHLORTHALIDONE | AGTR2, AGTR1, AGT | AGTR1 2/4885AGTR2 1/4885PPARG 195/4885 |
| US-20250352511-A1 | METHODS OF TREATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS WITH ATRASENTAN | REN, AGT, FRS2 | AGTR1 8/4885AGTR2 6/4885PPARG 759/4885 |
| US-20060281795-A1 | Benzinidazole Derivative and Use As AII Receptor Antagonist | AGTR1, AGTR2, GPR119 | AGTR1 1/4885AGTR2 2/4885PPARG 793/4885 |
| US-20050187269-A1 | Benzimidazole derivative and use thereof | REN, H1-3, GPR119 | AGTR1 18/4885AGTR2 40/4885PPARG 1288/4885 |
| US-20090270464-A1 | Benzimidazole derivative and use as a II receptor antagonist | AGTR1, BDKRB1, GPR119 | AGTR1 1/4885AGTR2 6/4885PPARG 598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.